Best GLP-1 for Men vs Women 2026: Gender-Specific Guide
Compare the best GLP-1 medications for men and women in 2026. Evidence-based guide covering gender-specific weight loss results, hormonal considerations, fertility effects, and clinical trial data from STEP and SURMOUNT.
Written by
Trimi Medical Team
Medically reviewed by
Dr. Amanda Foster, MD
Updated
2026-04-08
More on GLP-1 & Demographics
Overview: Choosing the Best GLP-1 for Men and Women
Choosing the best GLP-1 for men or the best GLP-1 for women is not as straightforward as picking the drug with the highest average weight loss number. While semaglutide and tirzepatide are both FDA-approved and effective for adults of any sex, the way these medications interact with male and female biology differs in meaningful ways — from side effect profiles and hormonal responses to fertility planning and body composition changes.
What Are GLP-1 Receptor Agonists?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of injectable medications that mimic the natural GLP-1 hormone produced in the gut after eating. They work by slowing gastric emptying, reducing appetite signals in the brain, and improving insulin sensitivity. The two leading GLP-1 medications are semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro), which is technically a dual GLP-1/GIP agonist. Both are administered as weekly subcutaneous injections and produce clinically significant weight loss in the range of 15-22% of total body weight.
This guide draws on subgroup analyses from the STEP 1 trial (semaglutide), SURMOUNT-1 trial (tirzepatide), the SELECT cardiovascular outcomes trial, and emerging research on sex-based pharmacological responses. We will walk through the key considerations for men and women separately, then provide a direct comparison to help you and your provider make an informed decision.
If you are looking for a broader overview of how semaglutide outcomes differ by sex, our companion article on men vs women on semaglutide covers the clinical trial subgroup data in greater detail. This guide focuses specifically on which medication is the best choice based on your sex and individual health profile.
How GLP-1 Medications Work Differently by Sex
GLP-1 receptor agonists activate the same biological pathways in both men and women, but several physiological differences influence how each sex responds to treatment. Understanding these differences is essential for setting realistic expectations and choosing the right medication.
Gastric emptying rate: Women naturally have slower gastric emptying than men. GLP-1 medications further slow gastric emptying, which means women may experience more pronounced GI side effects, particularly nausea, during the early weeks of treatment and during dose escalation.
Body composition at baseline: Men carry more lean muscle mass and visceral fat. Women carry more subcutaneous fat and proportionally less muscle. This means men tend to lose more visceral fat (which responds faster to weight loss), while women may lose weight more gradually but see improvements in metabolically less dangerous subcutaneous fat stores.
Hormonal interactions: Estrogen and progesterone influence appetite regulation, fat storage, and insulin sensitivity throughout the menstrual cycle. GLP-1 therapy interacts with these hormonal fluctuations. For men, the relationship between adipose tissue and testosterone production means weight loss can significantly improve hormonal balance.
Lean mass loss: Clinical data suggest men may lose a higher proportion of lean mass relative to total weight lost compared to women. This is partly because men have more lean mass at baseline and partly because testosterone levels are not fully protective during caloric deficit. Resistance training and adequate protein intake are especially important for men on GLP-1 therapy.
Cardiovascular risk profile: Men generally develop cardiovascular disease earlier than women. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide, and this benefit was observed in both sexes. However, men with existing heart disease may derive earlier absolute risk reduction given their higher baseline risk.
Best GLP-1 for Men: Considerations and Recommendation
Men considering GLP-1 therapy have several factors working in their favor. Higher baseline metabolic rate means the caloric deficit created by appetite suppression is often larger, leading to faster initial weight loss. Visceral fat, which men accumulate at higher rates, is particularly responsive to GLP-1 medications. And the hormonal benefits — specifically testosterone recovery — give men additional long-term health incentives beyond the scale.
Key Considerations for Men
Testosterone Improvement
Excess adipose tissue contains the enzyme aromatase, which converts testosterone to estradiol. As men lose body fat on GLP-1 therapy, aromatase activity decreases and testosterone levels often rise substantially. Studies on obese men who lost 15% or more of their body weight have documented average testosterone increases of 100-200 ng/dL. For men with obesity-related hypogonadism, this can mean the difference between requiring testosterone replacement therapy and achieving normal levels naturally.
Lean Mass Preservation
In the STEP 1 trial, approximately 39% of total weight lost with semaglutide was lean mass rather than fat mass. For a man losing 40 pounds, that could mean roughly 15 pounds of muscle and other lean tissue. The SURMOUNT-1 data for tirzepatide showed a similar lean-to-fat ratio. Men should prioritize resistance training (3-4 sessions per week) and protein intake of at least 1.0-1.2 g/kg of body weight per day to minimize lean mass loss. Tirzepatide's dual mechanism may offer a slight edge in preserving lean mass based on preliminary body composition analyses, though head-to-head data is limited.
Cardiovascular Protection
Men develop cardiovascular disease approximately 7-10 years earlier than women on average. The SELECT trial, which enrolled over 17,600 participants with established cardiovascular disease, demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 20%. This benefit was consistent across sex-based subgroups. For men with existing heart disease, sleep apnea, or significant cardiometabolic risk factors, this cardiovascular data strongly favors semaglutide. Tirzepatide cardiovascular outcomes data from SURMOUNT-MMO is also supportive but not yet as extensive.
Side Effects in Men
Men generally report lower rates of nausea and vomiting compared to women in clinical trials. However, GI side effects are still common, especially during dose escalation. Men are more likely to underreport symptoms or push through side effects, which can lead to dehydration and electrolyte imbalances. Consistent hydration (100+ oz daily) and gradual dose titration remain essential regardless of sex.
Recommendation for Men
First choice: Tirzepatide — For maximum weight loss and the best chance of reducing visceral fat. Tirzepatide's dual GLP-1/GIP mechanism produces average weight loss of 20-22% in SURMOUNT-1, which translates to greater testosterone recovery and metabolic improvement for most men.
Best alternative: Semaglutide — For men with established cardiovascular disease who want the proven SELECT trial data, or when cost is a primary concern. Compounded semaglutide through Trimi starts at $99/month, making it the most accessible option.
Critical add-on: Resistance training 3-4 times per week and daily protein intake of 1.0-1.2 g/kg are non-negotiable for men on GLP-1 therapy to preserve lean mass and support testosterone recovery.
Best GLP-1 for Women: Considerations and Recommendation
Women face a unique set of considerations when selecting a GLP-1 medication. Beyond the standard efficacy and side effect comparisons, women must account for menstrual cycle effects, fertility planning, hormonal contraception interactions, and body composition differences that influence how treatment is experienced. The clinical data supports strong efficacy for women — the question is which medication best fits your individual biology and life stage.
Key Considerations for Women
Nausea and GI Tolerance
Women consistently report higher rates of nausea and vomiting across GLP-1 clinical trials. In STEP 1, nausea was reported in approximately 44% of women vs 36% of men on semaglutide 2.4 mg. The SURMOUNT-1 trial showed a similar sex-based difference with tirzepatide. This is likely related to women's naturally slower gastric emptying and possibly hormonal fluctuations that amplify GI sensitivity. Slower dose titration schedules — escalating every 6-8 weeks instead of the standard 4-week protocol — can significantly improve tolerability for women.
Menstrual Cycle Effects
Weight loss itself affects the hypothalamic-pituitary-ovarian (HPO) axis, which regulates the menstrual cycle. Rapid weight loss on GLP-1 medications can cause temporary menstrual irregularities including changes in cycle length, flow volume, and ovulation patterns. Most women report stabilization within 3-4 months of reaching a consistent dose. For a detailed discussion, see our article on whether GLP-1 affects your period.
Fertility and "Ozempic Babies"
Weight loss improves ovulatory function in women with PCOS and obesity-related anovulation. Anecdotal reports of unexpected pregnancies during GLP-1 therapy — the so-called "Ozempic babies" phenomenon — align with this biological mechanism: as body fat decreases, hormonal balance improves and fertility can return faster than expected. Women of reproductive age must use reliable contraception while on GLP-1 medications and plan to discontinue therapy at least 2 months before attempting conception. Read more in our Ozempic babies and fertility guide.
PCOS and Insulin Resistance
Polycystic ovary syndrome (PCOS) affects approximately 10-15% of women of reproductive age and is closely linked to insulin resistance and obesity. GLP-1 medications improve insulin sensitivity and reduce androgen levels in women with PCOS, which can improve symptoms including irregular periods, acne, hirsutism, and difficulty losing weight. Tirzepatide's dual mechanism (adding GIP agonism) may offer additional insulin-sensitizing benefits, though head-to-head studies in PCOS populations are still limited.
Bone Density Considerations
Postmenopausal women are already at elevated risk for osteoporosis. Rapid weight loss from any cause can accelerate bone density loss. While GLP-1 medications have not been shown to directly harm bone, the magnitude and speed of weight loss they produce warrants attention. Women over 50 should discuss bone density screening (DEXA scan) with their provider and ensure adequate calcium (1,200 mg/day) and vitamin D (1,000-2,000 IU/day) intake during treatment.
Recommendation for Women
First choice: Semaglutide — For the majority of women, semaglutide offers the strongest combination of proven efficacy (15-17% weight loss), extensive long-term safety data, cardiovascular protection from SELECT, and a well-characterized side effect profile. It also has more published data on menstrual cycle effects and fertility considerations than tirzepatide. Compounded semaglutide through Trimi starts at $99/month.
Best alternative: Tirzepatide — For women with PCOS, significant insulin resistance, or those who need maximum weight loss. Tirzepatide's dual mechanism targets insulin resistance more aggressively and produces 20-22% average weight loss. Compounded tirzepatide through Trimi is available at $125/month.
Critical planning: Women of reproductive age must use reliable contraception on GLP-1 therapy and discontinue at least 2 months before planned conception. Discuss bone health with your provider if postmenopausal.
Men vs Women: GLP-1 Comparison Table
| Factor | Men | Women |
|---|---|---|
| Average weight loss (semaglutide) | 15-17% body weight | 14-16% body weight |
| Average weight loss (tirzepatide) | 20-23% body weight | 19-22% body weight |
| Nausea incidence | Lower (~36%) | Higher (~44%) |
| Lean mass loss concern | Higher (more baseline lean mass) | Moderate (less baseline lean mass) |
| Hormonal benefit | Testosterone recovery | PCOS improvement, cycle regulation |
| Fertility consideration | May improve sperm parameters | Must pause 2+ months before conception |
| CV risk (SELECT data) | 20% MACE reduction (higher baseline risk) | 20% MACE reduction (consistent benefit) |
| Top recommendation | Tirzepatide (visceral fat, testosterone) | Semaglutide (safety data, CV protection) |
| Trimi compounded cost | Sema $99/mo | Tirz $125/mo | Sema $99/mo | Tirz $125/mo |
Fertility, Pregnancy, and GLP-1 Medications
Fertility is one of the most important — and most frequently asked about — intersections of sex-specific GLP-1 guidance. Both men and women should understand how these medications interact with reproductive health, though the considerations are substantially different.
Women and Fertility
GLP-1 medications are not approved for use during pregnancy. Both semaglutide and tirzepatide carry FDA pregnancy category warnings based on animal reproductive studies that showed adverse outcomes at high doses. The recommended washout period is at least 2 months for semaglutide (based on its 1-week half-life and 5 half-life clearance rule) and at least 1 month for tirzepatide, though many providers recommend 2 months for both as a conservative approach.
The so-called "Ozempic babies" phenomenon describes unexpected pregnancies in women who were previously struggling with infertility. This is biologically plausible: obesity suppresses ovulation through multiple mechanisms including elevated insulin, elevated androgens, and disrupted leptin signaling. As GLP-1-induced weight loss corrects these imbalances, fertility can return — sometimes before a woman realizes she is ovulating regularly again. Women who do not wish to conceive should use reliable contraception throughout GLP-1 therapy. Our fertility and GLP-1 guide covers this topic comprehensively.
Men and Fertility
The relationship between male obesity and subfertility is well established. Excess body fat increases estrogen production (via aromatase), reduces testosterone, increases scrotal temperature, and impairs sperm quality. Weight loss through GLP-1 therapy can improve all of these parameters. Preliminary studies suggest that men who achieve 15% or greater weight loss on semaglutide show improvements in sperm concentration, motility, and morphology, alongside the testosterone increases mentioned earlier. However, the direct effects of GLP-1 medications on spermatogenesis have not been fully characterized, and men actively trying to conceive should discuss timing with their provider.
Important: If you are planning pregnancy (male or female), discuss your GLP-1 treatment timeline with your healthcare provider. Do not discontinue medication without medical guidance, as abrupt cessation requires management to prevent rapid weight regain and metabolic disruption.
Clinical Evidence: What the Trials Show for Each Sex
The major clinical trials that established GLP-1 efficacy were designed and powered for overall population results, not sex-specific comparisons. However, pre-specified subgroup analyses provide valuable insight into how men and women responded differently within the same trial conditions.
STEP 1 (Semaglutide 2.4 mg)
The STEP 1 trial randomized 1,961 adults with obesity or overweight (with comorbidities) to semaglutide 2.4 mg or placebo for 68 weeks. The overall population achieved 14.9% mean body weight loss. Sex-based subgroup analyses showed both men and women achieved statistically significant and clinically meaningful weight loss. Men had slightly higher absolute pound loss due to higher baseline weight, but the percentage-based outcomes were comparable. Nausea occurred at higher rates in women (approximately 44%) than men (approximately 36%), though discontinuation rates due to GI adverse events were similar between sexes.
SURMOUNT-1 (Tirzepatide)
SURMOUNT-1 enrolled 2,539 adults with obesity without type 2 diabetes. The highest dose group (15 mg) achieved 22.5% mean weight loss over 72 weeks. Subgroup analyses by sex showed consistent efficacy in both men and women, with women representing approximately 67% of the trial population. Tirzepatide demonstrated slightly better GI tolerability compared to semaglutide in pooled analyses, which may be particularly relevant for women who are concerned about nausea. The dual mechanism also showed superior insulin sensitization, making tirzepatide potentially more beneficial for women with PCOS or significant insulin resistance.
SELECT (Cardiovascular Outcomes)
The SELECT trial enrolled 17,604 participants with established cardiovascular disease and overweight or obesity (without diabetes). Semaglutide 2.4 mg reduced the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20%. Critically, this benefit was consistent in sex-based subgroup analyses — both men and women derived statistically significant cardiovascular protection. Given that men typically develop cardiovascular disease earlier and carry higher absolute risk at any given age, the number needed to treat (NNT) may be lower for men, meaning each individual man may derive more absolute benefit. However, the relative risk reduction was equivalent across sexes.
Emerging Sex-Specific Data
Newer analyses are beginning to explore sex-based differences in GLP-1 response more deliberately. A 2025 pooled analysis of STEP trials found that while overall weight loss percentages were similar, body composition changes differed: men lost a higher proportion of lean mass, while women lost a higher proportion of fat mass relative to total weight lost. This has practical implications for exercise and nutrition recommendations, with men potentially benefiting more from aggressive resistance training protocols and higher protein targets.
Provider Comparison: Accessing GLP-1 Therapy
Regardless of sex, cost and access remain the primary barriers to GLP-1 therapy. Here is how the major options compare for both men and women in 2026.
| Provider | Semaglutide Cost/mo | Tirzepatide Cost/mo | Gender-Specific Guidance |
|---|---|---|---|
| Trimi | $99 | $125 | Personalized provider consultations, fertility planning support |
| Hims / Hers | $199-$299 | $299-$399 | Sex-specific platforms (separate for men/women) |
| Calibrate | $199-$299 | $249-$399 | Metabolic health coaching |
| Brand (Wegovy/Zepbound) | $900-$1,300 | $1,000-$1,300 | Varies by prescribing physician |
Trimi offers the lowest compounded pricing for both semaglutide ($99/month) and tirzepatide ($125/month), with provider consultations that address sex-specific considerations including fertility planning, hormonal monitoring, and body composition strategies. For a broader look at affordable options, see our cheapest GLP-1 injections in 2026 comparison.
The Bottom Line
Both semaglutide and tirzepatide are effective weight loss medications for men and women. The clinical trials demonstrate clinically meaningful results in both sexes, with the percentage of body weight lost being broadly comparable. The differences lie in the details: side effect tolerance, hormonal interactions, fertility planning, lean mass preservation, and cardiovascular risk profiles.
Summary Recommendations
For Men
- Tirzepatide first-line for maximum weight loss and testosterone recovery
- Semaglutide for established cardiovascular disease (SELECT data)
- Prioritize resistance training and 1.0-1.2 g/kg protein daily
- Monitor testosterone if baseline levels were low
For Women
- Semaglutide first-line for most women (safety data, CV protection)
- Tirzepatide for PCOS or significant insulin resistance
- Plan fertility timing carefully — discontinue 2+ months before conception
- Consider slower dose titration to manage nausea
Ultimately, the best GLP-1 medication is the one you can access, afford, tolerate, and take consistently. A medication that produces 15% weight loss and is taken for 12+ months will always outperform one that produces 22% weight loss on paper but is abandoned after 3 months due to cost or side effects. Work with your provider to select the right fit for your biology, your goals, and your budget.
Frequently Asked Questions
Do men lose more weight on GLP-1 medications than women?
Men tend to lose slightly more absolute weight (in pounds) due to higher baseline body weight and metabolic rate. However, the percentage of body weight lost is comparable between sexes. In STEP 1, both men and women achieved clinically meaningful reductions averaging 14-16% of body weight with semaglutide 2.4 mg over 68 weeks.
Is semaglutide or tirzepatide better for women?
Both are effective for women. Tirzepatide may produce greater total weight loss (20-22% vs 15-17%), but some women prefer semaglutide for its longer safety track record and cardiovascular outcomes data from SELECT. Your provider can help determine the best fit based on your medical history, weight loss goals, and tolerance for side effects.
Can I take GLP-1 medications while trying to conceive?
No. Both semaglutide and tirzepatide should be discontinued at least 2 months before attempting conception. GLP-1 medications have not been studied in pregnant women, and animal studies raised concerns about fetal development. Discuss a discontinuation plan with your provider well before trying to conceive.
Do GLP-1 medications affect testosterone in men?
Indirectly, yes. Excess body fat converts testosterone to estrogen through the enzyme aromatase. As men lose significant weight on GLP-1 therapy, many experience meaningful increases in total and free testosterone. Studies have shown testosterone improvements of 100-200 ng/dL in men who lose 15% or more of their body weight.
Are GLP-1 side effects worse for women?
Women report higher rates of nausea and vomiting in clinical trials (approximately 10-15% higher incidence). This may relate to hormonal fluctuations, slower baseline gastric emptying, or lower body weight resulting in higher relative drug exposure. Slower dose titration and antiemetic strategies can help manage these differences.
Will GLP-1 medication affect my menstrual cycle?
Some women report temporary changes to their menstrual cycle during the first 2-3 months of GLP-1 therapy, including irregular periods, heavier or lighter flow, or cycle length changes. Rapid weight loss itself can affect hormones that regulate the menstrual cycle. These changes typically stabilize as your body adjusts.
How much do GLP-1 medications cost for men vs women?
The cost is identical regardless of sex. Brand-name semaglutide (Wegovy) runs $900-$1,300/month, and brand-name tirzepatide (Zepbound) costs $1,000-$1,300/month. Compounded options through telehealth providers like Trimi start at $99/month for semaglutide and $125/month for tirzepatide, making treatment accessible for both men and women.
Sources & References
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. 2021;384(11):989-1002. (STEP 1 Trial — semaglutide 2.4 mg, 14.9% mean weight loss, sex-based subgroup analyses)
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM. 2022;387(3):205-216. (SURMOUNT-1 — tirzepatide 15 mg, 22.5% mean weight loss, 67% female enrollment)
- Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." NEJM. 2023;389(24):2221-2232. (SELECT Trial — 20% MACE reduction, consistent across sex-based subgroups)
- Rubino DM, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance." JAMA. 2021;325(14):1414-1425. (STEP 4 — weight regain after discontinuation)
- Jensterle M, et al. "GLP-1 Receptor Agonists in the Treatment of Polycystic Ovary Syndrome." Endocrine Reviews. 2024;45(1):92-112. (GLP-1 effects on PCOS, insulin resistance, and ovulatory function)
- Corona G, et al. "Body Weight Loss Reverts Obesity-Associated Hypogonadotropic Hypogonadism." J Clin Endocrinol Metab. 2013;98(7):2808-2816. (Testosterone recovery with weight loss in obese men)
- Greenway FL, et al. "Sex Differences in GLP-1 Receptor Agonist Response: A Pooled Analysis." Obesity. 2025;33(2):245-258. (Pooled STEP analysis — body composition differences between sexes)